Abstract
Back ground: Prostate-Specific membrane Antigen has been known as a tumor associated neovasculature marker in some solid malignant tumors and targeting of that by cytotoxic- conjugated antibody can represent powerful tool for vascular targeted therapy in malignant tumors. In thyroid, it appears that angiogenesis factors are involved in neoplastic growth and aggressiveness of tumors. This study was conducted to evaluate the expression of PSMA as an angiogensis factor by immunohistochemistry in neovasculature of thyroid follicular neoplasms to determine its usefulness for distinguishing between adenoma and carcinoma . Methods: Paraffin Blocks of formalin fixed samples representing 48 cases of Follicular Thyroid adenoma and 15 cases of Follicular Thyroid Carcinoma were evaluated. Results: Among Carcinomas, capsular and vascular invasion were present in 12 and 11 cases , respectively. The intensity of PSMA staining was significantly higher in carcinoma group(p=0.028). However, no significant difference in extent of PSMA expression in adenoma and carcinoma groups was observed(p=0.239).Thyroid follicular cells in adenoma, carcinoma also non neoplastic area were negative for PSMA. Conclusion: Our findings do not support usefulness of PSMA in differentiating between FTA and FTC. However ; expression in neovasculature of differentiated thyroid tumors can represent a potential utility for PSMA-targeted radionuclide therapy in advanced differentiated thyroid cancers. DOI:10.21276/APALM.1511
Highlights
Thyroid cancers are the most common endocrine malignancies that have increased recently.[1]
We observed no significant difference in the extent of Prostate-Specific Membrane Antigen (PSMA) expression in adenoma and carcinoma groups (p=0.239).Thyroid follicular cells were negative for PSMA in adenoma, carcinoma and in non-neoplastic area
According to our findings, significant higher intensity of PSMA expression in Follicular Thyroid carcinoma (FTC) could be useful in differentiating between Follicular Thyroid Adenoma (FTA) and FTC
Summary
Thyroid cancers are the most common endocrine malignancies that have increased recently.[1]. [2] Thyroid lesions with follicular growth pattern are composed of a wide range including benign adenomatous nodule, Follicular Thyroid Adenoma (FTA), Follicular Thyroid carcinoma (FTC) and Follicular variant of Papillary Thyroid Carcinoma (FVPTC).[3,4,5]. One of the most challenging tasks in pathologic evaluation of thyroid follicular pattern lesion is distinction between FTC and FTA as a common benign thyroid nodule. Targeting of PSMA by cytotoxic- conjugated antibody can represent powerful tool for vascular targeted therapy. In thyroid, it appears that angiogenesis factors are involved in neoplastic growth and aggressiveness of tumors. This study was conducted to evaluate the expression of PSMA as an angiogenesis factor in neovasculature of thyroid follicular neoplasms by immunohistochemistry to determine its usefulness for distinguishing between adenoma and carcinoma
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
